HepC – Superinfection Therapeutics Inc. is a biopharmaceutical company leading the discovery and development of the innovative HepC – Superinfection technological platform for treatment of viral diseases by non-pathogenic viruses. HepC – Superinfection is uniquely positioned to leverage a mature therapeutic platform that harnesses the HepC – Superinfection drug discovery and development expertise of scientists, which founded the company. HepC – Superinfection has a well-balanced HepC – Superinfection therapeutic pipeline that had been clinically validated in HBV and HCV patients, an emerging HepC – Superinfection therapeutic platform to support its therapeutic programs, and a rich intellectual property estate. HepC – Superinfection intends to focus its proprietary efforts on developing HepC – Superinfection therapeutics for pandemic diseases such as, influenza and Ebola and is currently advancing its program toward clinical development in oncology. HepC – Superinfection’s commitment to innovation and its leadership in the superinfection field have enabled the formation of strategic alliances with ProBioGen AG in Germany, National Food Chain Safety Office (NFCSO), Szent István University (SzIE), Avidin Ltd. and University of Szeged, in Hungary, VectorLogics, Inc. and ImiGene, Inc. in the USA. In addition, the Company has established USA headquarters in collaboration with ImiGene Inc, in Rockville Maryland.